Arun Keepanasseril

Arun Keepanasseril

Auto-generated profile, based on publicly available information

Arun Keepanasseril

Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
RNRobby Nieuwlaat
Robby Nieuwlaat
NWNancy Wilczynski
Nancy Wilczynski
TNTamara Navarro
Tamara Navarro
NHNicholas Hobson
Nicholas Hobson
RJRebecca Jeffery
Rebecca Jeffery
RHR Brian Haynes
R Brian Haynes

21 January 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
FGFederico Germini
Federico Germini
NNNoella Noronha
Noella Noronha
VDVictoria Borg Debono
Victoria Borg Debono
BPBinu Abraham Philip
Binu Abraham Philip
DPDrashti Pete
Drashti Pete
AIAlfonso Iorio
Alfonso Iorio
Background: Numerous wrist-wearable devices to measure physical activity are currently available, but there is a need to unify the evidence on how they compare in terms of acceptability and accuracy. Objective: The aim of this study is to perform a systematic review of the literature to assess the accuracy and acceptability (willingness to use the device for the task it is designed to support) of wrist-wearable activity trackers. Methods: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and SPORTDiscus for studies measuring physical activity in the general population using wrist-wearable activity trackers. We screened articles for inclusion and, for the included studies, reported data on the studies’ setting and population, outcome measured, and risk of bias. Results: A total of 65 articles were included in our review. Accuracy was assessed for 14 different outcomes, which can be classified in the following categories: count of specific activities (including step counts), time spent being active, intensity of physical activity (including energy expenditure), heart rate, distance, and speed. Substantial clinical heterogeneity did not allow us to perform a meta-analysis of the results. The outcomes assessed most frequently were step counts, heart rate, and energy expenditure. For step counts, the Fitbit Charge (or the Fitbit Charge HR) had a mean absolute percentage error (MAPE) <25% across 20 studies. For heart rate, the Apple Watch had a MAPE 30% for all the brands, showing poor accuracy across devices. Acceptability was most frequently measured through data availability and wearing time. Data availability was ≥75% for the Fitbit Charge HR, Fitbit Flex 2, and Garmin Vivofit. The wearing time was 89% for both the GENEActiv and Nike FuelBand. Conclusions: The Fitbit Charge and Fitbit Charge HR were consistently shown to have a good accuracy for step counts and the Apple Watch for measuring heart rate. None of the tested devices proved to be accurate in measuring energy expenditure. Efforts should be made to reduce the heterogeneity among studies.

15 December 2016 in JMIR Research Protocols
Verified
Journal Article
Open access
AIAlfonso Iorio
Alfonso Iorio
AKArun Keepanasseril
Arun Keepanasseril
GFGary Foster
Gary Foster
TNTamara Navarro-Ruan
Tamara Navarro-Ruan
AMAlanna McEneny-King
Alanna McEneny-King
LTLehana Thabane
Lehana Thabane
Individual pharmacokinetic assessment is a critical component of tailored prophylaxis for hemophilia patients. Population pharmacokinetics allows using individual sparse data, thus simplifying individual pharmacokinetic studies. Implementing population pharmacokinetics capacity for the hemophilia community is beyond individual reach and requires a system effort. The Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) project aims to assemble a database of patient pharmacokinetic data for all existing factor concentrates, develop and validate population pharmacokinetics models, and integrate these models within a Web-based calculator for individualized pharmacokinetic estimation in patients at participating treatment centers. Individual pharmacokinetic studies on factor VIII and IX concentrates will be sourced from pharmaceutical companies and independent investigators. All factor concentrate manufacturers, hemophilia treatment centers (HTCs), and independent investigators (identified via a systematic review of the literature) having on file pharmacokinetic data and willing to contribute full or sparse pharmacokinetic data will be eligible for participation. Multicompartmental modeling will be performed using a mixed-model approach for derivation and Bayesian forecasting for estimation of individual sparse data. NONMEM (ICON Development Solutions) will be used as modeling software. The WAPPS-Hemo research network has been launched and is currently joined by 30 HTCs from across the world. We have gathered dense individual pharmacokinetic data on 878 subjects, including several replicates, on 21 different molecules from 17 different sources. We have collected sparse individual pharmacokinetic data on 289 subjects from the participating centers through the testing phase of the WAPPS-Hemo Web interface. We have developed prototypal population pharmacokinetics models for 11 molecules. The WAPPS-Hemo website (available at www.wapps-hemo.org, version 2.4), with core functionalities allowing hemophilia treaters to obtain individual pharmacokinetic estimates on sparse data points after 1 or more infusions of a factor concentrate, was launched for use within the research network in July 2015. The WAPPS-Hemo project and research network aims to make it easier to perform individual pharmacokinetic assessments on a reduced number of plasma samples by adoption of a population pharmacokinetics approach. The project will also gather data to substantially enhance the current knowledge about factor concentrate pharmacokinetics and sources of its variability in target populations. ClinicalTrials.gov NCT02061072; https://clinicaltrials.gov/ct2/show/NCT02061072 (Archived by WebCite at http://www.webcitation.org/6mRK9bKP6).

1 May 2015 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
BSBhairavi Sivaramalingam
Bhairavi Sivaramalingam
TNTamara Navarro
Tamara Navarro
NHNicholas Hobson
Nicholas Hobson
AKArun Keepanasseril
Arun Keepanasseril
RHR. Brian Haynes
R. Brian Haynes
We sought to review the effectiveness of interventions designed to improve adherence to antiretroviral therapy (ART) from studies included in a recent Cochrane review that reported a clinical and an adherence outcome, with at least 80% follow-up for 6 months or more. Data were extracted independently and in duplicate, with an adjudicator for disagreements. Risk of bias was assessed using the Cochrane Risk of Bias tool. Of 182 relevant studies in the Cochrane review, 49 were related to ART. Statistical pooling was not warranted due to heterogeneity in interventions, participants, treatments, adherence measures and outcomes. Many studies had high risk of bias in elements of design and outcome ascertainment. Only 10 studies improved both adherence and clinical outcomes. These used the following interventions: adherence counselling (two studies); a once-daily regimen (compared to twice daily); text messaging; web-based cognitive behavioral intervention; face-to-face multi-session intensive behavioral interventions (two studies); contingency management; modified directly observed therapy; and nurse-delivered home visits combined with telephone calls. Patient-related adherence interventions were the most frequently tested. Uniform adherence measures and higher quality studies of younger populations are encouraged.

28 February 2015 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
NMNiraj Mistry
Niraj Mistry
AKArun Keepanasseril
Arun Keepanasseril
NWNancy L. Wilczynski
Nancy L. Wilczynski
RNRobby Nieuwlaat
Robby Nieuwlaat
MRManthan Ravall
Manthan Ravall
TTthe Patient Adherence Review Team
the Patient Adherence Review Team
Background Despite effective therapies for many conditions, patients find it difficult to adhere to prescribed treatments. Technology-mediated interventions (TMIs) are increasingly being used with the hope of improving adherence. Objective To assess the effects of TMI, intended to enhance patient adherence to prescribed medications, on both medication adherence and clinical outcomes. Methods A secondary in-depth analysis was conducted of the subset of studies that utilized technology in at least one component of the intervention from an updated Cochrane review on all interventions for enhancing medication adherence. We included studies that clearly described an information and communication technology or medical device as the sole or major component of the adherence intervention. Results Thirty-eight studies were eligible for in-depth review. Only seven had a low risk of bias for study design features, primary adherence, and clinical outcomes. Eighteen studies used a TMI for education and/or counseling, 11 studies used a TMI for self-monitoring and/or feedback, and nine studies used electronic reminders. Studies used a variety of TMIs, with telephone the most common technology in use. Studies targeted a wide distribution of diseases and used a variety of adherence and clinical outcome measures. A minority targeted children and adolescents. Fourteen studies reported significant effects in both adherence and clinical outcome measures. Conclusions This review provides evidence for the inconsistent effectiveness of TMI for medication adherence and clinical outcomes. These results must be interpreted with caution due to a lack of high-quality studies.

26 May 2017 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AKA. Keepanasseril
A. Keepanasseril
JSJayson Stoffman
Jayson Stoffman
VBV. Bouskill
V. Bouskill
MCM. Carcao
M. Carcao
AIAlfonso Iorio
Alfonso Iorio
T(the Association of Hemophilia Centre Directors of Canada (AHCDC)
the Association of Hemophilia Centre Directors of Canada (AHCDC)